Ziopharm Oncology Inc. (NASDAQ:ZIOP) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $4.46 and last traded at $4.54, with a volume of 1,087,473 shares traded. The stock had previously closed at $4.60.

Several equities research analysts have recently issued reports on the stock. Mizuho reissued a “neutral” rating and set a $5.00 price objective (down previously from $7.00) on shares of Ziopharm Oncology in a research report on Monday. Wells Fargo & Co. reissued an “underperform” rating on shares of Ziopharm Oncology in a research report on Friday, July 15th. Griffin Securities reissued a “buy” rating and set a $21.00 price objective on shares of Ziopharm Oncology in a research report on Friday, July 1st. Raymond James Financial Inc. assumed coverage on shares of Ziopharm Oncology in a research report on Thursday, June 2nd. They set a “market perform” rating for the company. Finally, Zacks Investment Research downgraded shares of Ziopharm Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 31st. One analyst has rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $10.57.

The firm’s market capitalization is $591.18 million. The firm’s 50-day moving average price is $5.98 and its 200-day moving average price is $6.89.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. During the same quarter in the previous year, the company posted ($0.69) EPS. The company had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.89 million. Ziopharm Oncology’s revenue for the quarter was up 623.9% compared to the same quarter last year. On average, analysts forecast that Ziopharm Oncology Inc. will post ($0.42) EPS for the current year.

A number of large investors have bought and sold shares of ZIOP. California State Teachers Retirement System increased its stake in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 3,354 shares in the last quarter. Swiss National Bank increased its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the period. California Public Employees Retirement System increased its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the period. Finally, Morgan Stanley increased its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.